Commodore Capital LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001831942
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 33 positions · Total reported value $1.68B · Top-10 concentration 68.2% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 53.7% · 5 new · 9 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +32.0% · vs SPY +17.2% · Prev Value $1.73B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Commodore Capital LP disclosed 33 equity positions with a combined reported value of $1.68B. The filing implies a focused portfolio: its ten largest positions account for 68.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were RLAY ($224.52M), ELVN ($166.21M), ALKS ($157.19M). By sector, the heaviest allocations are Health Care 94.7%, Industrials 3.9%. Versus the prior quarter, allocation shifted toward Health Care (+3.3pp), Industrials (+1.8pp) and away from Other (-5.5pp).
Versus the prior quarter, Commodore Capital LP opened 5 new positions, trimmed 9 and fully exited 8, a turnover rate of 53.7% of positions. The portfolio's overlap with the prior quarter was 68% of names.
The largest new positions opened in Q2 2026 were TNGX ($70.33M), EDIT ($28.80M), IFRX ($16.35M).
Of the 8 positions fully exited versus the prior quarter, the largest were ERAS ($51.37M), XENE ($47.97M), NRIX ($35.26M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Fully Exited (vs previous quarter)
- ERAS ERASCA INC · prev qtr: $51.37M
- XENE XENON PHARMACEUTICALS INC · prev qtr: $47.97M
- NRIX NURIX THERAPEUTICS INC · prev qtr: $35.26M
- CRVS CORVUS PHARMACEUTICALS INC · prev qtr: $33.05M
- SLNO SOLENO THERAPEUTICS INC · prev qtr: $21.84M
- OCUL OCULAR THERAPEUTIX INC · prev qtr: $21.81M
- PALI PALISADE BIO INC · prev qtr: $12.57M
- KPTI KARYOPHARM THERAPEUTICS INC · prev qtr: $10.86M
Insider Transactions (Form 4)
Latest Commodore Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Commodore Capital LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 33 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-117168 (status: Approved), registered 2019-08-12
- Regulatory AUM (Form ADV): $2.37B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: commodorecapital.com
Portfolio Structure
- 33 positions · $1.68B reported value (Q2 2026)
- Top 10 holdings = 68.2% of reported value
- Largest position: RLAY (RELAY THERAPEUTICS INC COM) at 13.4%
- Average position size: $50.88M
Sector Tilt
- Health Care 94.7%
- Industrials 3.9%
- Financials 0.6%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 5 new, 6 added, 9 reduced, 8 exited
- 13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
12.00M | $224.52M | 13.37% | Reduce | |
| 2 |
|
3.27M | $166.21M | 9.90% | Hold | |
| 3 |
|
3.00M | $157.19M | 9.36% | Reduce | |
| 4 |
|
3.05M | $118.03M | 7.03% | Add | |
| 5 |
|
5.65M | $101.47M | 6.04% | Hold | |
| 6 |
|
2.00M | $94.08M | 5.60% | Hold | |
| 7 |
|
846.79K | $75.18M | 4.48% | Reduce | |
| 8 |
|
2.72M | $71.87M | 4.28% | Hold | |
| 9 |
|
2.25M | $70.33M | 4.19% | New | |
| 10 |
|
4.60M | $65.78M | 3.92% | Add | |
| 11 |
|
1.88M | $59.89M | 3.57% | Reduce | |
| 12 |
|
1.94M | $50.43M | 3.00% | Hold | |
| 13 |
|
1.35M | $50.23M | 2.99% | Reduce | |
| 14 |
|
1.43M | $49.28M | 2.94% | Reduce | |
| 15 |
|
1.50M | $48.68M | 2.90% | Hold | |
| 16 |
|
1.42M | $38.88M | 2.32% | Add | |
| 17 |
|
8.89M | $28.80M | 1.72% | New | |
| 18 |
|
250.00K | $28.67M | 1.71% | Reduce | |
| 19 |
|
6.34M | $21.61M | 1.29% | Hold | |
| 20 |
|
8.70M | $21.30M | 1.27% | Hold | |
| 21 |
|
3.25M | $19.18M | 1.14% | Hold | |
| 22 |
|
1.02M | $18.82M | 1.12% | Add | |
| 23 |
|
7.30M | $16.35M | 0.97% | New | |
| 24 |
|
2.93M | $14.20M | 0.85% | Add | |
| 25 |
|
100.00K | $12.35M | 0.74% | Reduce | |
| 26 |
|
2.87M | $11.19M | 0.67% | Reduce | |
| 27 |
|
5.40M | $10.96M | 0.65% | Hold | |
| 28 |
|
1.43M | $9.86M | 0.59% | Add | |
| 29 |
|
4.47M | $8.05M | 0.48% | Hold | |
| 30 |
|
500.00K | $5.35M | 0.32% | New | |
| 31 |
|
500.00K | $5.32M | 0.32% | Hold | |
| 32 |
|
464.40K | $4.27M | 0.25% | Hold | |
| 33 |
|
2.79M | $630.23K | 0.04% | New | |
FAQ
What did Commodore Capital LP buy in 2026-Q2?
In its 2026-Q2 13F filing, Commodore Capital LP reported 33 equity positions worth $1.68B in aggregate; its largest disclosed positions were RLAY ($224.52M), ELVN ($166.21M), ALKS ($157.19M).
How large is Commodore Capital LP's portfolio?
Commodore Capital LP reported $1.68B of long equity holdings across 33 positions as of 2026-Q2. Top-10 holdings account for 68.2% of reported value.
What is Commodore Capital LP's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.